“Alzheimer’s research is at a pivotal point,” said Dr. Jeffrey Cummings, Director at the Chambers-Grundy Center for Transformative Neuroscience.
TORONTO (PRWEB)
June 20, 2023
The Global Alzheimer’s Platform Foundation (GAP) is delighted to announce a collaborative, free webinar focusing on the current state of Alzheimer’s research and the innovative use of biomarkers in drug development. The event will delve into the latest advances, discussing the potential of blood-based and digital biomarkers in identifying key hallmarks of Alzheimer’s disease.
A disease that sees over 1,000 new diagnoses each day, Alzheimer’s research is in a race against time. In an effort to hasten this crucial research, GAP conducted its inaugural study, Bio-Hermes. This groundbreaking study evaluated the ability of promising biomarkers to reflect brain amyloid PET scans in participants, with a significant number of enrollees from racial and ethnic minority populations. This critical exploration into the correlation between diagnostic technologies and disease indicators is a stride toward more precise and inclusive diagnoses.
However, the sheer volume of data generated from such studies necessitates meticulous analysis. Pentara Corporation, a leader in data analysis, will discuss the importance of quality data, providing insights into how the Bio-Hermes data is positioned in this competitive environment.
“Alzheimer’s research is at a pivotal point,” said Dr. Jeffrey Cummings, Director at the Chambers-Grundy Center for Transformative Neuroscience. “The findings from the Bio-Hermes study have the potential to influence our understanding of the disease and how we approach its diagnosis and treatment.”
Join renowned speakers as they review the findings from the Bio-Hermes study and discuss the implications for Alzheimer’s research. The webinar aims to provide attendees with a deeper understanding of the advances in the most common blood and digital biomarkers for Alzheimer’s disease trials, the statistical relationship between individual biomarkers and the association between blood-based biomarkers and amyloid PET scans.
“Our mission at GAP is to accelerate the delivery of innovative therapies to those living with Alzheimer’s. This webinar is a step in that direction, and we’re excited to share our insights with the community,” said John Dwyer, President and CEO, Global Alzheimer’s Platform Foundation.
Join Dr. Jeffrey Cummings, Director, Chambers-Grundy Center for Transformative Neuroscience, UNLV; Dr. Richard Mohs, Chief Scientific Officer, Global Alzheimer’s Platform Foundation; Dr. Suzanne Hendrix, CEO, Pentara Corporation; and John Dwyer, President and CEO, Global Alzheimer’s Platform Foundation, for the live webinar on Monday, July 10, 2023, at 11am EDT (4pm BST/UK).
For more information, or to register for this event, visit Alzheimer’s and Biomarkers in Drug Development: The ABCD’s of Clinical Trial Innovation.
ABOUT XTALKS
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/
Contact:
Vera Kovacevic
Tel: +1 (416) 977-6555 x371
Email: vkovacevic@xtalks.com
Share article on social media or email: